Citas bibligráficas
Mori, P., (2024). Reacciones Adversas de la Metformina en pacientes diabéticos tipo 2 atendidos en el Centro de Salud Aranjuez Junio-Octubre 2022 [Universidad Nacional de Trujillo]. https://hdl.handle.net/20.500.14414/22443
Mori, P., Reacciones Adversas de la Metformina en pacientes diabéticos tipo 2 atendidos en el Centro de Salud Aranjuez Junio-Octubre 2022 []. PE: Universidad Nacional de Trujillo; 2024. https://hdl.handle.net/20.500.14414/22443
@misc{renati/883216,
title = "Reacciones Adversas de la Metformina en pacientes diabéticos tipo 2 atendidos en el Centro de Salud Aranjuez Junio-Octubre 2022",
author = "Mori Alva, Pamela Ximena",
publisher = "Universidad Nacional de Trujillo",
year = "2024"
}
ABSTRACT The objective of this thesis is to identify the adverse reactions to metformin in patients with type 2 diabetes who were treated at the Aranjuez Health Center between June and October 2022. For this purpose, a descriptive and retrospective analysis of reports on suspected adverse reactions and evaluation forms will be carried out. Adverse reactions to the use of medications are an ongoing challenge in the development of new drugs, as well as in maintaining their safety profile for patient use. Those with chronic conditions are the most exposed, as they require ongoing medication use. Diabetes is a metabolic disease considered by several studies as persistent in society and has a mortality rate associated with the patient’s clinical condition. In the initial phase of the study, participants signed a confidentiality agreement to ensure the protection of their physical and emotional integrity. The data was collected through direct interviews with the patients using a data collection form that included: full name, gender, age, height, weight, history of concomitant diseases, allergy history, concomitant medication, diagnosis, treatment, possible adverse reactions, duration of treatment in months, and observations. These data were subsequently analyzed using statistical techniques, such as the arithmetic mean (x=31), standard deviation (∂=9), and the coefficient of variation (CV=15%). Significant results were obtained, such as N=31 patients (59.6%) with mild adverse reactions, N=7 patients (13.5%) who experienced other types of adverse reactions not included in the technical sheet authorized by DIGEMID, N=12 patients (23.1%) who did not present any adverse reactions, and finally, N=2 patients, representing 3.8%, with both mild and other adverse reactions.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons